Prairiewood Capital LLC Sells 469 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Prairiewood Capital LLC cut its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 4.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,973 shares of the company’s stock after selling 469 shares during the period. Prairiewood Capital LLC’s holdings in Harmony Biosciences were worth $378,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC grew its position in Harmony Biosciences by 92.6% during the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock worth $31,000 after buying an additional 436 shares in the last quarter. Mendota Financial Group LLC lifted its stake in Harmony Biosciences by 24,125.0% during the fourth quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock worth $33,000 after purchasing an additional 965 shares during the period. CWM LLC lifted its stake in Harmony Biosciences by 111.7% during the third quarter. CWM LLC now owns 1,469 shares of the company’s stock worth $59,000 after purchasing an additional 775 shares during the period. Quarry LP acquired a new stake in Harmony Biosciences during the second quarter valued at approximately $62,000. Finally, Quantbot Technologies LP bought a new stake in shares of Harmony Biosciences in the 3rd quarter valued at approximately $74,000. 86.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Harmony Biosciences

In other news, insider Jeffrey Dierks sold 21,496 shares of the stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $40.47, for a total transaction of $869,943.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 30.80% of the company’s stock.

Harmony Biosciences Trading Up 1.3 %

HRMY opened at $39.05 on Tuesday. The firm’s fifty day simple moving average is $34.46 and its 200 day simple moving average is $34.96. The stock has a market capitalization of $2.23 billion, a P/E ratio of 18.51, a P/E/G ratio of 0.49 and a beta of 0.78. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. Harmony Biosciences Holdings, Inc. has a 12 month low of $28.14 and a 12 month high of $41.61.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $0.79 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.15. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The company had revenue of $186.00 million during the quarter, compared to analysts’ expectations of $184.07 million. During the same period in the prior year, the firm earned $0.63 earnings per share. Harmony Biosciences’s revenue for the quarter was up 16.0% compared to the same quarter last year. As a group, research analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.42 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have issued reports on HRMY shares. Mizuho increased their price objective on Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a research note on Thursday, October 10th. Raymond James reiterated an “outperform” rating and set a $40.00 target price on shares of Harmony Biosciences in a research report on Thursday, October 10th. Cantor Fitzgerald raised their price target on Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a report on Wednesday, October 30th. Oppenheimer reaffirmed an “outperform” rating and set a $59.00 target price (up previously from $56.00) on shares of Harmony Biosciences in a report on Wednesday, October 30th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $52.00 price target on shares of Harmony Biosciences in a research note on Monday, January 13th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $55.00.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.